Experimental cell therapy aims to tame severe, untreatable autoimmune diseases
NCT ID NCT06255028
Summary
This early-stage study is testing a new cell therapy called CNTY-101 in people with severe autoimmune diseases like lupus, lupus nephritis, and scleroderma that have not improved with other treatments. The main goals are to find a safe dose and see if the therapy helps control the diseases. The therapy works by using specially modified immune cells to target and reduce harmful B cells thought to drive these conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch
Seattle, Washington, 98109, United States
-
Keck School of Medicine of University of Southern California
Los Angeles, California, 90033, United States
-
Lurie Children's; Northwestern Medicine - Northwestern Medical Group
Chicago, Illinois, 60611, United States
-
Primary Children's Hospital
Salt Lake City, Utah, 84113, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
UC Davis
Sacramento, California, 957817, United States
Conditions
Explore the condition pages connected to this study.